-
Something wrong with this record ?
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
MG. Della Porta, H. Tuechler, L. Malcovati, J. Schanz, G. Sanz, G. Garcia-Manero, F. Solé, JM. Bennett, D. Bowen, P. Fenaux, F. Dreyfus, H. Kantarjian, A. Kuendgen, A. Levis, J. Cermak, C. Fonatsch, MM. Le Beau, ML. Slovak, O. Krieger, M....
Language English Country England, Great Britain
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Validation Study
NLK
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Medline Complete (EBSCOhost)
from 1997-01-01 to 2015-11-30
Nursing & Allied Health Database (ProQuest)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2000-01-01 to 1 year ago
PubMed
25721895
DOI
10.1038/leu.2015.55
Knihovny.cz E-resources
- MeSH
- Cytogenetic Analysis MeSH
- Adult MeSH
- Risk Assessment MeSH
- Combined Modality Therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- International Cooperation MeSH
- Survival Rate MeSH
- Adolescent MeSH
- Young Adult MeSH
- Myelodysplastic Syndromes classification diagnosis mortality therapy MeSH
- Follow-Up Studies MeSH
- Prognosis MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- World Health Organization * MeSH
- Research Design MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Validation Study MeSH
A risk-adapted treatment strategy is mandatory for myelodysplastic syndromes (MDS). We refined the World Health Organization (WHO)-classification-based Prognostic Scoring System (WPSS) by determining the impact of the newer clinical and cytogenetic features, and we compared its prognostic power to that of the revised International Prognostic Scoring System (IPSS-R). A population of 5326 untreated MDS was considered. We analyzed single WPSS parameters and confirmed that the WHO classification and severe anemia provide important prognostic information in MDS. A strong correlation was found between the WPSS including the new cytogenetic risk stratification and WPSS adopting original criteria. We then compared WPSS with the IPSS-R prognostic system. A highly significant correlation was found between the WPSS and IPSS-R risk classifications. Discrepancies did occur among lower-risk patients in whom the number of dysplastic hematopoietic lineages as assessed by morphology did not reflect the severity of peripheral blood cytopenias and/or increased marrow blast count. Moreover, severe anemia has higher prognostic weight in the WPSS versus IPSS-R model. Overall, both systems well represent the prognostic risk of MDS patients defined by WHO morphologic criteria. This study provides relevant in formation for the implementation of risk-adapted strategies in MDS.
Cleveland Clinic Cleveland OH USA
Department of Hematology VU University Medical Center Amsterdam The Netherlands
Division of Hematology Stanford University Cancer Center Stanford CA USA
Elisabethinen Hospital Linz Austria
Federal University of Ceara Fortaleza Brazil
Fondazione Italiana Sindromi Mielodisplastiche c o SS Antonio e Biagio Hospital Alessandria Italy
Georg August Universität Göttingen Germany
Hanusch Hospital and L Boltzmann Cluster Oncology Vienna Austria
Hanusch Hospital Boltzmann Institute for Leukemia Research Vienna Austria
Heinrich Heine University Hospital Düsseldorf Germany
Hôpital Avicenne Assistance Publique Hôpitaux de Paris University Paris XIII Bobigny France
Hôpital Cochin AP HP University of Paris 5 Paris France
Hospital Universitario La Fe Valencia Spain
Hospital Universitario Vall d'Hebron Barcelona Spain
Institut de Recerca contra la Leucèmia Josep Carreras Barcelona Spain
Institute of Hematology and Blood Transfusion Praha Czech Republic
James P Wilmot Cancer Institute University of Rochester Medical Center Rochester NY USA
Medical University of Vienna Vienna Austria
Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan
Quest Diagnostics Nichols Institute Chantilly VA USA
St James's University Hospital Leeds UK
The University of Texas MD Anderson Cancer Center Houston TX USA
University of Chicago Comprehensive Cancer Research Center Chicago IL USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15031449
- 003
- CZ-PrNML
- 005
- 20170529141508.0
- 007
- ta
- 008
- 151005s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/leu.2015.55 $2 doi
- 035 __
- $a (PubMed)25721895
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Della Porta, M G $u 1] Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy [2] Department of Internal Medicine, University of Pavia, Pavia, Italy.
- 245 10
- $a Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) / $c MG. Della Porta, H. Tuechler, L. Malcovati, J. Schanz, G. Sanz, G. Garcia-Manero, F. Solé, JM. Bennett, D. Bowen, P. Fenaux, F. Dreyfus, H. Kantarjian, A. Kuendgen, A. Levis, J. Cermak, C. Fonatsch, MM. Le Beau, ML. Slovak, O. Krieger, M. Luebbert, J. Maciejewski, SM. Magalhaes, Y. Miyazaki, M. Pfeilstöcker, MA. Sekeres, WR. Sperr, R. Stauder, S. Tauro, P. Valent, T. Vallespi, AA. van de Loosdrecht, U. Germing, D. Haase, PL. Greenberg, M. Cazzola,
- 520 9_
- $a A risk-adapted treatment strategy is mandatory for myelodysplastic syndromes (MDS). We refined the World Health Organization (WHO)-classification-based Prognostic Scoring System (WPSS) by determining the impact of the newer clinical and cytogenetic features, and we compared its prognostic power to that of the revised International Prognostic Scoring System (IPSS-R). A population of 5326 untreated MDS was considered. We analyzed single WPSS parameters and confirmed that the WHO classification and severe anemia provide important prognostic information in MDS. A strong correlation was found between the WPSS including the new cytogenetic risk stratification and WPSS adopting original criteria. We then compared WPSS with the IPSS-R prognostic system. A highly significant correlation was found between the WPSS and IPSS-R risk classifications. Discrepancies did occur among lower-risk patients in whom the number of dysplastic hematopoietic lineages as assessed by morphology did not reflect the severity of peripheral blood cytopenias and/or increased marrow blast count. Moreover, severe anemia has higher prognostic weight in the WPSS versus IPSS-R model. Overall, both systems well represent the prognostic risk of MDS patients defined by WHO morphologic criteria. This study provides relevant in formation for the implementation of risk-adapted strategies in MDS.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a cytogenetické vyšetření $7 D020732
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mezinárodní spolupráce $7 D007391
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a myelodysplastické syndromy $x klasifikace $x diagnóza $x mortalita $x terapie $7 D009190
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a výzkumný projekt $7 D012107
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a míra přežití $7 D015996
- 650 12
- $a Světová zdravotnická organizace $7 D014944
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a validační studie $7 D023361
- 700 1_
- $a Tuechler, H $u Hanusch Hospital, Boltzmann Institute for Leukemia Research, Vienna, Austria.
- 700 1_
- $a Malcovati, L $u 1] Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy [2] Department of Molecular Medicine, University of Pavia, Pavia, Italy.
- 700 1_
- $a Schanz, J $u Georg August Universität, Göttingen, Germany.
- 700 1_
- $a Sanz, G $u Hospital Universitario La Fe, Valencia, Spain.
- 700 1_
- $a Garcia-Manero, G $u The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
- 700 1_
- $a Solé, F $u Institut de Recerca contra la Leucèmia Josep Carreras, Barcelona, Spain.
- 700 1_
- $a Bennett, John M., $u James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. $d 1933- $7 xx0213919
- 700 1_
- $a Bowen, D $u St James's University Hospital, Leeds, UK.
- 700 1_
- $a Fenaux, P $u Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP)/University Paris XIII, Bobigny, France.
- 700 1_
- $a Dreyfus, F $u Hôpital Cochin, AP-HP University of Paris V, Paris, France.
- 700 1_
- $a Kantarjian, H $u The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
- 700 1_
- $a Kuendgen, A $u Heinrich-Heine University Hospital, Düsseldorf, Germany.
- 700 1_
- $a Levis, A $u Fondazione Italiana Sindromi Mielodisplastiche c/o SS Antonio e Biagio Hospital, Alessandria, Italy.
- 700 1_
- $a Cermak, J $u Institute of Hematology and Blood Transfusion, Praha, Czech Republic.
- 700 1_
- $a Fonatsch, C $u Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Le Beau, M M $u University of Chicago Comprehensive Cancer Research Center, Chicago, IL, USA.
- 700 1_
- $a Slovak, M L $u Quest Diagnostics Nichols Institute, Chantilly, VA, USA.
- 700 1_
- $a Krieger, O $u Elisabethinen Hospital, Linz, Austria.
- 700 1_
- $a Luebbert, M $u University of Freiburg Medical Center, Freiburg, Germany.
- 700 1_
- $a Maciejewski, J $u Cleveland Clinic, Cleveland, OH, USA.
- 700 1_
- $a Magalhaes, S M M $u Federal University of Ceara, Fortaleza, Brazil.
- 700 1_
- $a Miyazaki, Y $u Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- 700 1_
- $a Pfeilstöcker, M $u Hanusch Hospital and L. Boltzmann Cluster Oncology, Vienna, Austria.
- 700 1_
- $a Sekeres, M A $u Cleveland Clinic, Cleveland, OH, USA.
- 700 1_
- $a Sperr, W R $u Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Stauder, R $u Hanusch Hospital and L. Boltzmann Cluster Oncology, Vienna, Austria.
- 700 1_
- $a Tauro, S $u University of Dundee, Dundee, Scotland, UK.
- 700 1_
- $a Valent, P $u Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Vallespi, T $u Hospital Universitario Vall d'Hebron, Barcelona, Spain.
- 700 1_
- $a van de Loosdrecht, A A $u Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
- 700 1_
- $a Germing, U $u Heinrich-Heine University Hospital, Düsseldorf, Germany.
- 700 1_
- $a Haase, D $u Georg August Universität, Göttingen, Germany.
- 700 1_
- $a Greenberg, P L $u Division of Hematology, Stanford University Cancer Center, Stanford, CA, USA.
- 700 1_
- $a Cazzola, M $u 1] Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy [2] Department of Molecular Medicine, University of Pavia, Pavia, Italy.
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 29, č. 7 (2015), s. 1502-13
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25721895 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20170529141910 $b ABA008
- 999 __
- $a ok $b bmc $g 1092325 $s 914575
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 29 $c 7 $d 1502-13 $e 20150227 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20151005
